ClinicalTrials.gg
CompletedNCT03480997Updated Mar 29, 2018

Acute Bronchodilator Effect of Inhaled Albuterol Sulfate and Ipratropium Bromide in Patients With Stable COPD

A Phase 1 interventional study of Albuterol Sulfate and Ipratropium Bromide and Albuterol Sulfate in COPD, sponsored by Pneuma Respiratory, Inc. Completed at 1 site in United States. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-03-29.

Sponsored by Pneuma Respiratory, Inc · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Apr 2017, 9 years 6 months ago, and no results have been posted to the registry.
  • Registered 1 year 2 months after the study started (first participant enrolled Dec 2016, registered Mar 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
46
Allocation
Non-randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 27 studies testing albuterol in Pulmonary Disease, Chronic Obstructive — none open to participants now, 1 under way, none of them phase 3. Albuterol · Pulmonary Disease, Chronic Obstructive.

Enrollment
12th of 27
46 · median 33
Started
2016
with 1 other
Phase 1
5 of 27
none open now
Registered
24th of 27
by date

Among the 27 studies testing albuterol in Pulmonary Disease, Chronic Obstructive, this one is the 12th largest by enrollment, is one of 2 that started in 2016, is one of 5 in phase 1, and was the 24th registered.

Pulmonary Disease, Chronic Obstructive

5,528 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

None of the 27 studies testing albuterol in Pulmonary Disease, Chronic Obstructive is open now. The open studies under Pulmonary Disease, Chronic Obstructive, anywhere →

About albuterol

Albuterol: first FDA approval 1981 (PROVENTIL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 561 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 27 studies testing albuterol in Pulmonary Disease, Chronic Obstructive as a file.
02

Study summary

The purpose of this study is to demonstrate the pharmacodynamic bioequivalence of the test product to the reference product as measured by increases in FEV1.

Read the detailed description

A single center, open label, single dose study to demonstrate the pharmacodynamic bioequivalence of the test and reference metered dose inhalers containing albuterol sulfate or albuterol sulfate/ipratropium in adult patients with COPD.

03

Conditions studied

04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provide written
  • Diagnosis of as defined by the American Thoracic Society/European Respiratory Society guidelines characterized by progressive airflow limitation associated with abnormal inflammatory response of the lungs to noxious particles or gases primarily caused by cigarette smoking.
  • Have an established COPD clinical history, symptomatic with dyspnea, chronic cough, chronic sputum production or wheezing. At Visit 1, /FVC ratio must be less than 0.70 or at least 10% less than the FEV1/FVC ratio determined by the predicted normal value. FEV1 must be less than 70% of the predicted normal value and greater than 25% of the predicted normal value.
  • Must be using one or more inhaled bronchodilators for treatment of COPD at the time of Visit 1.
  • Current or former smokers, with a history of at least 10 pack-years of cigarette smoking. Number of pack-years = (number of cigarettes per day/20) X (number of years smoked).
  • Willing, and in the opinion of the investigator, able to adjust current COPD therapy as required by the protocol.

Exclusion criteria

Exclusion Criteria:

  • Current diagnosis of other respiratory disorder(s) including, but not limited to: alpha-1-antitrypsin deficiency; lung cancer; cystic fibrosis; tuberculosis; sarcoidosis; idiopathic pulmonary fibrosis; primary pulmonary hypertension; or pulmonary thromboembolic disease. Patients with concomitant and asthma will be allowed to participate.
  • Diagnosis of non-respiratory disorder(s) that are currently affecting lung function, as determined by he principal investigator including, but not limited to: congestive heart failure; symptomatic cardiac arrhythmia; symptomatic seizure disorder; dementia; lupus; rheumatoid arthritis; or liver cirrhosis.
  • Unable to abstain from protocol defined prohibited medications during the screening and testing period.
  • Unable to withhold short acting bronchodilators for 6 hours prior to spirometry testing at the study visit.
  • Unable to perform acceptable or repeatable spirometry or comply with other study procedures.
  • Known allergic reaction to albuterol sulfate or ipratropium bromide.
  • Diagnosis of cancer that is not presumed to be in remission or cured.
  • Active alcohol or drug abuse.
  • Pregnant or lactating women. Pregnancy confirmed by a positive hCG test.
  • Treatment with another study drug in another clinical study within the last 30 days or five half-lives, whichever is longer.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    albuterol sulfate 100 mcg

    albuterol sulfate 100 mcg Test MDI

    Combination Product: Albuterol Sulfate

  • Active comparator
    albuterol sulfate 200 mcg

    albuterol sulfate 200 mcg Reference MDI

    Combination Product: Albuterol Sulfate

  • Experimental
    albuterol sulfate and ipratropium bromide

    albuterol sulfate 100 mcg and ipratropium bromide 20 mcg Test MDI

    Combination Product: Albuterol Sulfate and Ipratropium Bromide

Interventions

06

What researchers measure

Primary outcomes

  1. Primary Efficacy Endpoint: Change in FEV1

    Change in FEV1

    Time frame: Just prior to dosing and twenty minutes post dosing

07

Study locations

1 site
  • Advanced Respiratory and Sleep Medicine, PLLC
    Hickory, North Carolina 28601, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2016 to primary completion in Apr 2017, 4 months.

Of 158 industry-sponsored phase 1 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 9. This study's 4 months is close to that.

Counting every sponsor, half of 176 studies reached it within 4 months; a quarter within 2 and three quarters within 11.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2018
First posted
Mar 29, 2018
StartActual
Dec 27, 2016
Primary completionActual
Apr 28, 2017
CompletionActual
Apr 28, 2017
Last update
Mar 29, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 29, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03480997
Lead sponsor
Pneuma Respiratory, Inc
Responsible party
Sponsor
First posted
Mar 29, 2018
Start date
Dec 27, 2016
Primary completion
Apr 28, 2017
Completion
Apr 28, 2017
Last update
Mar 29, 2018

Study contacts

Tom Stern, MD
principal investigator · Advanced Respiratory and Sleep Medicine, PLLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Albuterol · Ipratropium

Start the discussion